This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Lotus Ventures Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Lotus Ventures's earnings have been declining at an average annual rate of -19.3%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 20.7% per year.
Belangrijke informatie
-19.3%
Groei van de winst
-7.3%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 7.3% |
| Inkomstengroei | 20.7% |
| Rendement op eigen vermogen | -20.5% |
| Nettomarge | -93.7% |
| Laatste winstupdate | 31 Aug 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Lotus Ventures geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Aug 23 | 2 | -2 | 1 | 0 |
| 31 May 23 | 2 | -6 | 1 | 0 |
| 28 Feb 23 | 2 | -6 | 1 | 0 |
| 30 Nov 22 | 1 | -6 | 1 | 0 |
| 31 Aug 22 | 2 | -5 | 1 | 0 |
| 31 May 22 | 2 | 0 | 1 | 0 |
| 28 Feb 22 | 3 | 0 | 1 | 0 |
| 30 Nov 21 | 5 | 1 | 1 | 0 |
| 31 Aug 21 | 5 | 0 | 2 | 0 |
| 31 May 21 | 6 | 0 | 2 | 0 |
| 28 Feb 21 | 6 | 1 | 2 | 0 |
| 30 Nov 20 | 6 | 0 | 2 | 0 |
| 31 Aug 20 | 5 | 1 | 1 | 0 |
| 31 May 20 | 3 | 1 | 1 | 0 |
| 29 Feb 20 | 1 | -1 | 2 | 0 |
| 30 Nov 19 | 0 | -1 | 2 | 0 |
| 31 Aug 19 | 0 | -3 | 3 | 0 |
| 31 May 19 | 0 | -2 | 2 | 0 |
| 28 Feb 19 | 0 | -3 | 3 | 0 |
| 30 Nov 18 | 0 | -3 | 3 | 0 |
| 31 Aug 18 | 0 | -3 | 2 | 0 |
| 31 May 18 | 0 | -2 | 2 | 0 |
| 28 Feb 18 | 0 | -2 | 2 | 0 |
| 30 Nov 17 | 0 | -1 | 1 | 0 |
| 31 Aug 17 | 0 | -1 | 1 | 0 |
| 31 May 17 | 0 | -1 | 1 | 0 |
| 28 Feb 17 | 0 | -1 | 1 | 0 |
| 30 Nov 16 | 0 | -1 | 1 | 0 |
| 31 Aug 16 | 0 | -1 | 1 | 0 |
| 31 May 16 | 0 | -1 | 1 | 0 |
| 29 Feb 16 | 0 | -1 | 1 | 0 |
| 30 Nov 15 | 0 | -1 | 1 | 0 |
| 31 Aug 15 | 0 | -1 | 0 | 0 |
| 31 May 15 | 0 | -1 | 0 | 0 |
Kwaliteitswinsten: LV9 is currently unprofitable.
Groeiende winstmarge: LV9 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: LV9 is unprofitable, and losses have increased over the past 5 years at a rate of 19.3% per year.
Versnelling van de groei: Unable to compare LV9's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: LV9 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Rendement op eigen vermogen
Hoge ROE: LV9 has a negative Return on Equity (-20.54%), as it is currently unprofitable.